Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sapanisertib + tamoxifen
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of sapanisertib (TAK-228), an oral, highly selective inhibitor of mTORC1/2, and tamoxifen, a selective estrogen receptor modulator. Sapanisertib inhibits both mammalian target of rapamycin complex 1 (mTORC1) and mTORC2, which are involved in cellular growth, proliferation, and survival pathways frequently dysregulated in cancer.
02
Targets
ER (Estrogen receptor)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on sapanisertib + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sapanisertib + tamoxifen.